Skip to content
AnalystLens

Neurocrine Biosciences 8-K/A Report, Exhibit Filing (Jul 31, 2026)

Reports
Exhibits & Filings
Filing Date
Filed July 31, 2026
Period End
May 14, 2026
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · Apr ’21Apr ’21
  3. Leadership change8-K · May ’25May ’25

Summary

Summary of the 8-K/A filed July 31, 2026. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. filed this Amendment No. 1 on Form 8-K/A to amend its May 18, 2026 Current Report, which reported the completion of its merger with Soleno Therapeutics, Inc. The amendment adds Soleno's audited consolidated financial statements for the year ended December 31, 2025 (Exhibit 99.1), its unaudited interim condensed consolidated financial statements for the three months ended March 31, 2026 (Exhibit 99.2), and unaudited pro forma condensed combined statements of income for the six months ended June 30, 2026 and the year ended December 31, 2025 (Exhibit 99.3).

The filing states that it does not update any other item or discuss developments after the original report's filing date. The acquisition, completed on May 18, 2026 at a price of $53.00a per Soleno share in cash, added VYKAT XR (diazoxide choline), described as a first-in-class therapy for hyperphagia in Prader-Willi syndrome. The pro forma statements, prepared under the acquisition method with Neurocrine as the accounting acquirer, show pro forma total revenues of $1,907.5 million and net income of $294.0 million for the six months ended June 30, 2026, and total revenues of $3,050.9 million and net income of $324.5 million for 2025.

Diluted pro forma earnings per share are $2.83b and $3.17, respectively. The statements exclude synergies and cost savings, and the company describes the fair value estimates as preliminary, with the purchase accounting to be finalized within one year of the closing date. Financing was provided through a May 14, 2026 credit agreement for a five-year, $1.0 billion senior secured revolving credit facility.

The company drew $600.0 millionc on May 18, 2026 at an initial rate of 4.896% (Term SOFR plus 1.25%) and had repaid the full amount as of June 30, 2026. The filing also reports an estimated $2,237.8 million fair value for the VYKAT XR intangible asset, with a 16-year useful life, and a $168.2 million inventory fair value step-up.

Key Highlights

  1. Neurocrine completed its acquisition of Soleno Therapeutics on May 18, 2026, paying $53.00 per share in cash and adding VYKAT XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome.
  2. Pro forma total revenues were $1,907.5 million for the six months ended June 30, 2026 and $3,050.9 million for the year ended December 31, 2025.
  3. Pro forma net income was $294.0 million for the six months ended June 30, 2026 and $324.5 million for 2025, with diluted EPS of $2.83 and $3.17, respectively.
  4. The VYKAT XR intangible asset has an estimated fair value of $2,237.8 million and a 16-year useful life, producing incremental amortization of $53.6 million for the six months ended June 30, 2026 and $139.9 million for 2025.
  5. A $1.0 billion five-year senior secured revolving credit facility was entered into on May 14, 2026; $600.0 million was drawn on May 18, 2026 and fully repaid as of June 30, 2026.
  6. Transaction costs of approximately $33.1 million were recorded in the six months ended June 30, 2026, and a $168.2 million inventory fair value step-up is expected to flow through cost of revenues.
  7. Purchase accounting estimates are preliminary; a 10% change in intangible asset valuation would change amortization by about $7.0 million for the six months and $13.9 million for 2025.

Frequently Asked Questions

  1. What was the purchase price and what did Neurocrine acquire?

    Neurocrine acquired all outstanding shares of Soleno Therapeutics, Inc. at $53.00 per share in cash. The acquisition closed on May 18, 2026 and added VYKAT XR (diazoxide choline), a first-in-class therapy for hyperphagia in Prader-Willi syndrome.

  2. How does the acquisition affect Neurocrine's pro forma results?

    On a pro forma basis, total revenues were $1,907.5 million for the six months ended June 30, 2026 and $3,050.9 million for 2025. Pro forma net income was $294.0 million and $324.5 million for those periods, respectively. The statements assume the deal closed on January 1, 2025 and exclude synergies and cost savings.

  3. How was the acquisition financed?

    Neurocrine entered into a five-year, $1.0 billion senior secured revolving credit facility with JPMorgan Chase Bank, N.A. as administrative agent on May 14, 2026. It drew $600.0 million on May 18, 2026 at an initial rate of 4.896%, calculated as Term SOFR plus 1.25%, and had repaid the full balance as of June 30, 2026.

  4. Why could the reported figures change?

    The filing describes the fair value estimates of assets acquired and liabilities assumed as preliminary, and the company intends to finalize the acquisition accounting within one year of the closing date. A 10% change in the valuation of intangible assets would change amortization by approximately $7.0 million for the six months ended June 30, 2026 and $13.9 million for 2025.